| アブストラクト | BACKGROUND: Combination therapy comprised of fluoropyrimidine plus irinotecan with an angiogenesis inhibitor is widely used as a second-line treatment for metastatic colorectal cancer (mCRC). PATIENTS AND METHODS: This retrospective study evaluated the efficacy and safety of fluorouracil and irinotecan (FOLFIRI) plus ramucirumab (RAM); FOLFIRI plus aflibercept (AFL); irinotecan and S-1 (IRIS) plus bevacizumab (BEV); and capecitabine and irinotecan (CAPIRI) plus BEV, with FOLFIRI plus BEV serving as the control among mCRC patients who failed treatment with fluoropyrimidine and oxaliplatin plus BEV. Data were collected from a medical claim database provided by Medical Data Vision Co., Ltd. (Tokyo, Japan). The primary outcome was time to treatment failure (TTF). Secondary outcomes were time to first subsequent therapy (TFST), overall survival (OS), and safety. RESULTS: Among 3,136 patients assessed, TTF was significantly shorter with FOLFIRI plus RAM (adjusted hazard ratio [HR], 1.40; 95% confidence interval [CI], 1.26-1.56; P < .001) and FOLFIRI plus AFL (HR, 1.34; 95% CI, 1.09-1.66; P = .002), and significantly longer with IRIS plus BEV (HR, 0.80; 95% CI, 0.70-0.92; P = .002). TFST was significantly shorter with FOLFIRI plus RAM (HR, 1.32; 95% CI, 1.17-1.49; P < .001); no significant difference in OS was observed. The incidences of neutropenia requiring granulocyte colony-stimulating factor were significantly lower with IRIS plus BEV and CAPIRI plus BEV. CONCLUSION: Regarding TTF, BEV seemed to be a favorable option compared with RAM and AFL when combined with FOLFIRI, and IRIS might be preferable compared to FOLFIRI when combined with BEV for patients who failed to respond to fluoropyrimidine, oxaliplatin, and BEV. |
|---|
| ジャーナル名 | Clinical colorectal cancer |
|---|
| 投稿日 | 2021/4/21 |
|---|
| 投稿者 | Yamazaki, Kentaro; Yuki, Satoshi; Oki, Eiji; Sano, Fumikazu; Makishima, Misako; Aoki, Kenichi; Hamano, Tetsutaro; Yamanaka, Takeharu |
|---|
| 組織名 | Division of Gastrointestinal Oncology, Shizuoka Cancer Center, Shizuoka, Japan.;Electronic address: k.yamazaki@scchr.jp.;Department of Gastroenterology and Hepatology, Hokkaido University Hospital,;Sapporo, Japan.;Department of Surgery and Science, Graduate School of Medical Sciences, Kyushu;University, Fukuoka, Japan.;Medical Affairs Division, Chugai Pharmaceutical Co., Ltd., Tokyo, Japan.;P4 Statistics Co. Ltd., Tokyo, Japan.;Department of Biostatistics, Yokohama City University School of Medicine,;Yokohama, Japan. |
|---|
| Pubmed リンク | https://www.ncbi.nlm.nih.gov/pubmed/33875364/ |
|---|
